FDA & Product Rules

HHS Lets Pharmacies Compound BPC-157 and Five Other Peptides but Leaves Research-Use Sellers Out

HHS's October 28, 2026 interim enforcement discretion policy lets 503A pharmacies and physicians compound BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax under ten conditions, without adding them to the bulks list. Research-use-only sellers are left out, and comments close November 13.

E-commerce 4 Internet Marketers Editorial
FDA & Product Rules

Mississippi Pharmacy Board Says a Certificate of Analysis Does Not Clear Research-Grade Peptides

The Mississippi Board of Pharmacy's October 2026 newsletter says a certificate of analysis alone does not satisfy the state's joint peptide statement, that human-use disclaimers do not prevent enforcement, and that out-of-state telehealth prescribers need a Mississippi license.

E-commerce 4 Internet Marketers Editorial
FDA & Product Rules

FDA Peptide Warning Letters Show Research Use Only Labels Did Not Shield Online Vendors

FDA's August 24, 2026 warning letters to Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and Tex Peptides set aside research use only disclaimers and list the product pages, study summaries, blog posts, calculators, and bacteriostatic water that FDA treated as evidence of intended human use.

E-commerce 4 Internet Marketers Editorial